Qiagen Jumps into Personalized Medicine with Purchase of Companion Diagnostic Firm DxS

In acquiring DxS, Qiagen is attempting to increase its presence in molecular diagnostic-based personalized healthcare. Meantime, coming under the Qiagen umbrella is likely to provide a relatively small personalized medicine firm like DxS a global reach and more negotiating clout with large pharma and biotechs.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.